Vision, Integrity, Expertise
Soligenix, Inc. is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation.
orBec®
orBec® represents a first-of-its-kind oral, locally acting therapy tailored to treat the GI manifestation of GVHD by reducing the need for systemic immunosuppressive drugs to treat GI GVHD. Click here to learn more about orBec®.
Latest News
Tuesday, June 29, 2010
Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDTFriday, June 25, 2010
Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ AdministrationWednesday, June 16, 2010
Soligenix Announces Private Equity Financing of $5.16 Million with its Partner Sigma-Tau and other Institutional InvestorsPartnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.